S
ALLO icon

SignatureFD’s Allogene Therapeutics ALLO Stock Holding History

SignatureFD’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Sell
7,057
-1,793
-20% -$3.94K ﹤0.01% 2486
2026
Q1 		$21.6K Buy
8,850
+4,795
+118% +$9.61K ﹤0.01% 2161
2025
Q4 		$5.55K Sell
4,055
-301
-7% -$397 ﹤0.01% 2651
2025
Q3 		$5.4K Buy
4,356
+2,803
+180% +$3.34K ﹤0.01% 2638
2025
Q2 		$1.75K Sell
1,553
-5,837
-79% -$7.76K ﹤0.01% 2901
2025
Q1 		$10.8K Buy
7,390
+5,304
+254% +$10K ﹤0.01% 2323
2024
Q4 		$4.44K Sell
2,086
-115
-5% -$284 ﹤0.01% 2646
2024
Q3 		$6.16K Buy
2,201
+1,600
+266% +$4.26K ﹤0.01% 2510
2024
Q2 		$1.4K Sell
601
-3,657
-86% -$10.8K ﹤0.01% 2834
2024
Q1 		$19K Buy
4,258
+106
+3% +$442 ﹤0.01% 2020
2023
Q4 		$13.3K Sell
4,152
-1,798
-30% -$5.1K ﹤0.01% 2126
2023
Q3 		$18.9K Buy
5,950
+2,040
+52% +$8.94K ﹤0.01% 1878
2023
Q2 		$19.4K Buy
3,910
+525
+16% +$2.84K ﹤0.01% 1906
2023
Q1 		$16.7K Buy
3,385
+2,817
+496% +$18.1K ﹤0.01% 1961
2022
Q4 		$3.57K Sell
568
-2,001
-78% -$18.5K ﹤0.01% 2605
2022
Q3 		$28K Hold
2,569
– – ﹤0.01% 1572
2022
Q2 		$29K Buy
2,569
+1,709
+199% +$15.2K ﹤0.01% 1573
2022
Q1 		$8K Buy
860
+831
+2,866% +$8.65K ﹤0.01% 2240
2021
Q4 		$0 Sell
29
-71
-71% -$1.25K ﹤0.01% 3093
2021
Q3 		$3K Buy
100
+70
+233% +$1.66K ﹤0.01% 2496
2021
Q2 		$1K Buy
30
+3
+11% +$86 ﹤0.01% 2668
2021
Q1 		$1K Buy
+27
New +$911 ﹤0.01% 2582
2020
Q4 		– Sell
-42
Closed -$2K – 2540
2020
Q3 		$2K Buy
+42
New +$1.58K ﹤0.01% 2164
2020
Q2 		– Sell
-132
Closed -$3K – 2479
2020
Q1 		$3K Buy
+132
New +$3.14K ﹤0.01% 1784

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SignatureFD's ALLO Position: Q2 2026 in Review

SignatureFD reduced its Allogene Therapeutics (ALLO) stake by 20% in Q2 2026, selling an estimated $3.94K and leaving 7,057 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

SignatureFD first reported a position in ALLO in Q1 2020 and has held it in 24 quarters since. The position peaked at $29K in Q2 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • SignatureFD held 7,057 shares of Allogene Therapeutics worth $14.7K as of Q2 2026.
  • SignatureFD sold 1,793 Allogene Therapeutics shares in Q2 2026, an estimated $3.94K.
  • Allogene Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2486 holding.
  • SignatureFD first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • SignatureFD's Allogene Therapeutics position peaked at $29K in Q2 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.